Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    NCT01178944
Show Display Options
Rank Status Study
1 Completed Pralatrexate and Oxaliplatin in Treating Patients With Unresectable or Metastatic Esophageal, Stomach, or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Esophageal Undifferentiated Carcinoma;   Gastric Adenocarcinoma;   Gastric Squamous Cell Carcinoma;   Recurrent Esophageal Adenocarcinoma;   Recurrent Esophageal Squamous Cell Carcinoma;   Recurrent Gastric Carcinoma;   Stage IIIB Esophageal Adenocarcinoma;   Stage IIIB Esophageal Squamous Cell Carcinoma;   Stage IIIB Gastric Cancer;   Stage IIIC Esophageal Adenocarcinoma;   Stage IIIC Esophageal Squamous Cell Carcinoma;   Stage IIIC Gastric Cancer;   Stage IV Esophageal Adenocarcinoma;   Stage IV Esophageal Squamous Cell Carcinoma;   Stage IV Gastric Cancer;   Undifferentiated Gastric Carcinoma
Interventions: Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Drug: Pralatrexate

Study has passed its completion date and status has not been verified in more than two years.